nach oben

Erschienen in:

03.09.2019 | Meta-Analysis

Association between nonalcoholic fatty liver disease and cardiac function and structure—a meta-analysis

verfasst von: Marta Borges-Canha, João Sérgio Neves, Diogo Libânio, Madalena Von-Hafe, Catarina Vale, Miguel Araújo-Martins, Ana Rita Leite, Pedro Pimentel-Nunes, Davide Carvalho, Adelino Leite-Moreira

Erschienen in: Endocrine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Nonalcoholic fatty liver disease is increasingly recognized as the hepatic counterpart of metabolic syndrome. It is hypothesized that structural and functional cardiac changes may be associated with this metabolic disease. We aimed to gather the existing information on the association of nonalcoholic fatty liver disease with cardiac alterations, and to evaluate a possible correlation between them.

Methods

Systematic review of Medline searching results for original articles studying NAFLD and cardiac parameters until August 2018. A meta-analysis was conducted to each parameter of cardiac structure and function selected, using Review Manager 5.3 software. This study was conducted according to preferred reporting items for systematic reviews and meta-analysis (PRISMA).

Results

A total of 16 studies met the eligibility criteria and were included in the meta-analysis. There was a significant association between nonalcoholic fatty liver disease and (1) higher left ventricle mass and ratios between left ventricle mass and both height and body surface area; (2) higher LVEDD; (3) higher left atrium diameter and ratio between left atrial volume and body surface area; (4) higher posterior wall and septum thickness; (5) lower E/A wave ratio; (6) higher E/E’ ratio; (7) longer deceleration time and (8) longer relaxation time.

Conclusion

NAFLD associates with adverse structural alterations and cardiac dysfunction. Our results highlight the importance of identifying NAFLD in patients with metabolic dysfunction as this may represent an additional contributor to cardiovascular risk.

Nur mit Berechtigung zugänglich

M. Borges Canha, J.P. Portela-Cidade, G. Conceicao, C. Sousa-Mendes, S. Leite, D. Fontoura et al. Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome. Rev. Esp. Enferm. Dig. 109(7), 491–497 (2017). https://doi.org/10.17235/reed.2017.4575/2016.CrossRefPubMed

Z.M. Younossi, A.B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, M. Wymer, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73–84 (2016). https://doi.org/10.1002/hep.28431.CrossRefPubMed

N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, K. Cusi et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142(7), 1592–1609 (2012). https://doi.org/10.1053/j.gastro.2012.04.001.CrossRefPubMed

M. Ekstedt, H. Hagstrom, P. Nasr, M. Fredrikson, P. Stal, S. Kechagias et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5), 1547–1554 (2015). https://doi.org/10.1002/hep.27368.CrossRefPubMed

K. Wijarnpreecha, S. Lou, P. Panjawatanan, W. Cheungpasitporn, S. Pungpapong, F.J. Lukens et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig. Liver Dis. 50(11), 1166–1175 (2018). https://doi.org/10.1016/j.dld.2018.09.004.CrossRefPubMed

S.H. Wan, M.W. Vogel, H.H. Chen, Pre-clinical diastolic dysfunction. J. Am. Coll. Cardiol. 63(5), 407–416 (2014). https://doi.org/10.1016/j.jacc.2013.10.063.CrossRefPubMed

A.O. Baktir, B. Sarli, R.E. Altekin, A. Karaman, H. Arinc, H. Saglam et al. Non alcoholic steatohepatitis is associated with subclinical impairment in left ventricular function measured by speckle tracking echocardiography. Anatol. J. Cardiol. 15(2), 137–142 (2015). https://doi.org/10.5152/akd.2014.5212.CrossRefPubMed

A. Bekler, E. Gazi, G. Erbag, E. Binnetoglu, A. Barutcu, H. Sen et al. Right ventricular function and its relationship with grade of hepatosteatosis in non-alcoholic fatty liver disease. Cardiovasc J. Afr. 26(3), 109–113 (2015). https://doi.org/10.5830/CVJA-2014-068.CrossRefPubMedPubMedCentral

S. Bonapace, G. Perseghin, G. Molon, G. Canali, L. Bertolini, G. Zoppini et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 35(2), 389–395 (2012). https://doi.org/10.2337/dc11-1820.CrossRefPubMedPubMedCentral

10.

G.E. Chung, J.H. Lee, H. Lee, M.K. Kim, J.Y. Yim, S.Y. Choi et al. Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis 272, 137–144 (2018). https://doi.org/10.1016/j.atherosclerosis.2018.03.027.CrossRefPubMed

11.

F. Fallo, A. Dalla Pozza, N. Sonino, M. Lupia, F. Tona, G. Federspil et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr. Metab. Cardiovasc. Dis. 19(9), 646–653 (2009). https://doi.org/10.1016/j.numecd.2008.12.007.CrossRefPubMed

12.

H. Fotbolcu, T. Yakar, D. Duman, T. Karaahmet, K. Tigen, C. Cevik et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol. J. 17(5), 457–463 (2010). Epub 2010/09/25.PubMed

13.

S. Goland, S. Shimoni, T. Zornitzki, H. Knobler, O. Azoulai, G. Lutaty et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 40(10), 949–955 (2006). https://doi.org/10.1097/01.mcg.0000225668.53673.e6.CrossRefPubMed

14.

J.Y. Jung, S.K. Park, J.H. Ryoo, C.M. Oh, J.G. Kang, J.H. Lee et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol. Res. 47(6), 522–532 (2017). https://doi.org/10.1111/hepr.12770.CrossRefPubMed

15.

N.H. Kim, J. Park, S.H. Kim, Y.H. Kim, D.H. Kim, G.Y. Cho et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100(12), 938–943 (2014). https://doi.org/10.1136/heartjnl-2013-305099.CrossRefPubMed

16.

A. Mantovani, M. Pernigo, C. Bergamini, S. Bonapace, P. Lipari, I. Pichiri et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS ONE 10(8), e0135329 (2015). https://doi.org/10.1371/journal.pone.0135329.CrossRefPubMedPubMedCentral

17.

A. Metwaly, A.A. Khalik, F.M. Nasr, A.I. Sabry, M.F. Gouda, M. Hassan, Brain natriuretic peptide in liver cirrhosis and fatty liver: correlation with cardiac performance. Electron Physician 8(2), 1984–1993 (2016). https://doi.org/10.19082/1984.CrossRefPubMedPubMedCentral

18.

A. Niaz, Z. Ali, S. Nayyar, N. Fatima, Prevalence of NAFLD in healthy and young male individuals. ISRN Gastroenterol. 2011, 363546 (2011). https://doi.org/10.5402/2011/363546.CrossRefPubMedPubMedCentral

19.

T.G. Simon, D.G. Bamira, R.T. Chung, R.B. Weiner, K.E. Corey, Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity 25(8), 1313–1316 (2017). https://doi.org/10.1002/oby.21879.CrossRefPubMed

20.

M. Sunbul, T. Kivrak, E. Durmus, H. Akin, Y. Aydin, R. Ergelen et al. Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc Ther. 33(5), 294–299 (2015). https://doi.org/10.1111/1755-5922.12145.CrossRefPubMed

21.

F.M. Trovato, G.F. Martines, D. Catalano, G. Musumeci, C. Pirri, G.M. Trovato, Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J. Cardiol. 221, 275–279 (2016). https://doi.org/10.1016/j.ijcard.2016.06.180.CrossRefPubMed

22.

L.B. VanWagner, J.E. Wilcox, L.A. Colangelo, D.M. Lloyd-Jones, J.J. Carr, J.A. Lima et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62(3), 773–783 (2015). https://doi.org/10.1002/hep.27869.CrossRefPubMedPubMedCentral

23.

G. Wells, B. Shea, D. O’Connell, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses; 2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2 Nov 2015.

24.

J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency in meta-analyses. BMJ 327(7414), 557–560 (2003). https://doi.org/10.1136/bmj.327.7414.557.CrossRefPubMedPubMedCentral

25.

E. Bonci, C. Chiesa, P. Versacci, C. Anania, L. Silvestri, L. Pacifico, Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis. Biomed. Res Int. 2015, 213737 (2015). https://doi.org/10.1155/2015/213737.CrossRefPubMedPubMedCentral

26.

Q.M. Anstee, A. Mantovani, H. Tilg, G. Targher, Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 15(7), 425–439 (2018). https://doi.org/10.1038/s41575-018-0010-0.CrossRefPubMed

27.

E. Bugianesi, Nonalcoholic fatty liver disease (NAFLD) and cardiac lipotoxicity: another piece of the puzzle. Hepatology 47(1), 2–4 (2008). https://doi.org/10.1002/hep.22105.CrossRefPubMed

28.

L.S. Bhatia, N.P. Curzen, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur. Heart J. 33(10), 1190–1200 (2012). https://doi.org/10.1093/eurheartj/ehr453.CrossRefPubMed

29.

E.D. Abel, K.M. O’Shea, R. Ramasamy, Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler. Thromb. Vasc. Biol. 32(9), 2068–2076 (2012). https://doi.org/10.1161/ATVBAHA.111.241984.CrossRefPubMedPubMedCentral

Titel: Association between nonalcoholic fatty liver disease and cardiac function and structure—a meta-analysis
verfasst von: Marta Borges-Canha
João Sérgio Neves
Diogo Libânio
Madalena Von-Hafe
Catarina Vale
Miguel Araújo-Martins
Ana Rita Leite
Pedro Pimentel-Nunes
Davide Carvalho
Adelino Leite-Moreira
Publikationsdatum: 03.09.2019
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02070-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

A nomogram for predicting the presence of germline mutations in pheochromocytomas and paragangliomas

The tendency of reduced periodontal destruction in acromegalic patients showing similar inflammatory status with periodontitis patients

Unusual uptake of 131iodine in bilateral ovarian endometriosis cysts in a patient with thyroid cancer

Spectral domain optical coherence tomography based imaging biomarkers for diabetic retinopathy

Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer